Recently, the National Health and Family Planning Commission issued a letter on the official website on the "Proposal to put the issue of "low-cost life-saving" old medicine supply security as soon as possible on the agenda," the reply said that in recent years, the Ministry of Industry and Information Technology Joint Development and Reform Commission The Ministry of Finance and other departments have supported the GMP transformation of the shortage of pharmaceutical manufacturers through relevant industrialization special projects. In the special project of industrial revitalization and technological transformation, the expansion of clinical shortage medicines, rare diseases and children's medicines is the support focus. 30 projects implemented technical transformation and arranged funds of about 300 million yuan. At the same time, in 2016, through the industrial transformation and upgrading of the "three products" of the consumer goods, the special products for rare diseases such as rare diseases, new vaccines, suitable dosage forms for children, and the industrialization of children in clinical shortages will be supported. 80 million yuan. In addition, the reply mentioned that according to the current policy, eligible low-cost pharmaceutical manufacturers can obtain corresponding support policies in terms of bank loans. The current enterprise income tax law provides a series of income tax incentives that encourage technological innovation, including For high-tech enterprises, the enterprise income tax may be levied at a reduced rate of 15%; the eligible research and development expenses incurred by the enterprise may be deducted from the income tax on the basis of actual deduction; 50% of the eligible fixed assets of the enterprise Depreciation can be accelerated, and small and profit-making enterprises that meet the conditions can enjoy the levy of corporate income tax, etc., and eligible pharmaceutical manufacturers can enjoy the above-mentioned tax benefits according to law. For projects such as planting and processing “low-cost life-saving†pharmaceutical raw materials that meet the requirements of comprehensive agricultural development policies, you can apply for support from local agricultural development agencies. According to the reply, the next step will be the national shortage of medicine supply guarantee work by the State Health Planning Commission, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Finance, the Ministry of Human Resources and Social Welfare, the Ministry of Commerce, the State-owned Assets Supervision and Administration Commission, the State Administration for Industry and Commerce, and the Food and Drug Administration. The business linkage mechanism highlights cross-sectoral and multi-sectoral policy coordination, collaboration and effective linkage, clear work rules and task division, comprehensive use of fixed-point production, emergency production and coordinated import, improvement of pharmaceutical reserve system, docking of supply and demand information, and improper combat Acts and improve the policy of rare disease medications, etc., to improve the government's ability to supply clinically necessary, small-volume, and enterprises with insufficient production capacity. The provincial health and family planning departments will coordinate relevant departments to establish corresponding consultation mechanisms to comprehensively evaluate drugs within the jurisdiction. Shortage information and countermeasures, comprehensively solve the problem of partial shortage, focus on strengthening provincial, prefecture, and county level monitoring, timely analyze, process, report shortage information, and enhance comprehensive response capabilities. The shortage of cheap drugs has intensified in recent years. According to relevant reports, cheap drugs are disappearing in the market at a rate of more than a dozen per year. The disappearance of cheap drugs not only affects residents' use of drugs, but also causes modern medical systems to encounter "diagnosis". You can't afford medicine or "have a diagnosis but no medicine is available." In addition, some cheap "life-saving drugs" are not sold in normal hospitals and pharmacies, and sales in certain gray channels also disrupt the normal pharmaceutical circulation market order. To this end, the relevant functional parts of the state have introduced policies to supervise the normal supply of cheap drugs. In June 2017, the National Health and Safety Commission and the National Development and Reform Commission and other eight departments, "Implementation Opinions on Reforming and Perfecting the Shortage Drug Supply Guarantee Mechanism" clearly stated that the establishment and improvement The national shortage of drug supply guarantee work consultation mechanism, rationally define the shortage of clinical essential drugs, develop a list of shortage drugs and organize the comprehensive clinical evaluation of drugs in the list, and build a multi-source information collection and supply business for the shortage of drugs at the national and provincial levels. Platform, establish and improve a mature and stable shortage of real-time monitoring and early warning and grading response system. In November 2017, Premier Li Keqiang gave an indication to the media that “the leukemia suffers from a shortage of cheap domestically produced drugs and one bottle of imported drugs exceeds 1,000 yuanâ€, requiring relevant departments to “effectively increase the supply and supply of domestically produced cheap drugsâ€. On the road to the protection of cheap drugs, some people in the industry said that the state should continue to promote the reform of the medical and health system, protect people's demand for drugs, and at the same time solve the problem of expensive medical treatment for the people. The cheap "special effects drugs" must guarantee sustainable supply, not only the country needs To improve the operation mechanism of cheap "special effects drugs", it is also necessary to improve the management of drug production, use and reserves. Injectable Skin Rejuvenating Solution Jiangsu Tiera Biotechnology Co., Ltd , https://www.tierabio.com